Dan Lou
Directeur/Bestuurslid bij China Medicinal Biotech Association
Profiel
Dan Lou was the founder of Shenyang Sunshine Pharmaceuticals Co., Ltd.
founded in 1993 and 3SBio, Inc. founded in 1993 where he held the title of Executive Chairman from 2011 to 2012.
He currently holds a position as Executive Director at China Medicinal Biotech Association.
Mr. Lou received his undergraduate degree from Third Military Medical University in 1955.
Actieve functies van Dan Lou
| Bedrijven | Functie | Begin |
|---|---|---|
| China Medicinal Biotech Association | Directeur/Bestuurslid | 18-10-2011 |
Eerdere bekende functies van Dan Lou
| Bedrijven | Functie | Einde |
|---|---|---|
| 3SBIO INC. | Oprichter | 01-04-2012 |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
 Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Oprichter | - |
Opleiding van Dan Lou
| Third Military Medical University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| 3SBIO INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| China Medicinal Biotech Association | |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Health Technology |
